Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Brevibloc
Generic Name
Esmolol Hydrochloride
Active Ingredient
EsmololCategory
Other
Salt Form
Hydrochloride
Variants
8
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Brevibloc, you must consult a qualified healthcare professional.
| 20 mg/mL | INJECTION | INTRAVENOUS | 10019-666 |
| 10 mg/mL | INJECTION | INTRAVENOUS | 10019-670 |
| 20 mg/mL | INJECTION | INTRAVENOUS | 10019-075 |
| 10 mg/mL | INJECTION | INTRAVENOUS | 10019-672 |
| 10 mg/mL | INJECTION | INTRAVENOUS | 0404-9825 |
Detailed information about Brevibloc
Esmolol is an ultra-short-acting, cardioselective beta-1 adrenergic blocker used primarily in clinical settings for the rapid control of ventricular rate and blood pressure during acute cardiac events or surgery.
Esmolol dosing is highly individualized and based on the patient’s body weight and clinical response. Healthcare providers typically use a 'loading dose' followed by a 'maintenance infusion' to achieve rapid steady-state concentrations.
Esmolol is not currently FDA-approved for use in pediatric patients. However, in specialized pediatric intensive care units (PICU), it is sometimes used off-label for the management of hypertensive crises or tachyarrhythmias. Pediatric dosing, when used, is strictly calculated by weight and monitored by pediatric cardiologists. Parents should be aware that safety and efficacy have not been formally established for children by the manufacturer.
No dosage adjustment of Esmolol itself is required for patients with kidney disease because it is metabolized in the blood. However, the acid metabolite (ASL-8123) is excreted by the kidneys and can accumulate in patients with end-stage renal disease. Caution and close monitoring are advised.
Because Esmolol is metabolized by red blood cell esterases rather than the liver, no dosage adjustment is necessary for patients with liver cirrhosis or hepatic failure.
Clinical studies have shown that elderly patients may be more sensitive to the blood-pressure-lowering effects of Esmolol. Healthcare providers typically start at the lower end of the dosing range and monitor blood pressure more frequently.
Esmolol is administered only by a healthcare professional through an intravenous (IV) line. It is never self-administered.
Since Esmolol is administered as a continuous infusion in a hospital setting by medical staff, the risk of a 'missed dose' in the traditional sense is non-existent. If an infusion is accidentally interrupted, the drug’s short half-life means its effects will wear off within minutes, and the medical team will restart the infusion immediately to regain control of the heart rate.
An overdose of Esmolol can lead to serious cardiovascular depression. Symptoms include:
Emergency Measures: If an overdose occurs, the infusion is stopped immediately. Because the drug clears the body so fast, symptoms often resolve quickly. However, supportive treatments such as Atropine (for slow heart rate), IV fluids, or vasopressors (to raise blood pressure) may be administered by the medical team.
> Important: Follow your healthcare provider's dosing instructions. Do not attempt to adjust or request changes to your IV settings without medical guidance.
The most frequently reported side effect of Esmolol is hypotension (low blood pressure). According to clinical trial data, up to 20-50% of patients may experience some degree of blood pressure drop.
Esmolol is a potent cardiovascular medication that requires expert administration. The most critical safety point is that Esmolol must be continuously monitored via electrocardiogram (ECG) and frequent blood pressure checks. Because its effects are so rapid, changes in a patient's status can occur in minutes. It should only be used in settings where resuscitative equipment and trained personnel are immediately available.
No FDA black box warnings for Esmolol. Unlike some other beta-blockers (like Atenolol or Propranolol), Esmolol does not carry a black box warning for the 'Exacerbation of Ischemic Heart Disease upon Abrupt Withdrawal.' This is largely because Esmolol is used for short-term acute care, though caution is still required when transitioning a patient from Esmolol to longer-acting oral medications.
There are no absolute 'never use' combinations in an emergency, but certain drugs create such high risk that they are generally avoided:
Esmolol must NEVER be used in the following conditions because the risks significantly outweigh any potential benefits:
Esmolol is classified as FDA Pregnancy Category C. This means that there are no adequate and well-controlled studies in pregnant women. Animal studies have shown some evidence of fetal toxicity at high doses.
It is not known whether Esmolol is excreted in human milk. However, because many drugs are excreted in milk and because of the potential for serious adverse reactions in nursing infants (such as slow heart rate and low blood pressure), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Given Esmolol's 9-minute half-life, the drug clears the mother's system very quickly after the infusion stops.
Esmolol is a beta-1 selective (cardioselective) adrenergic receptor blocker. At therapeutic doses, it preferentially inhibits the beta-1 receptors located in the heart muscle. It has little to no 'intrinsic sympathomimetic activity' (ISA) and no 'membrane stabilizing activity' at clinical doses.
By blocking beta-1 receptors, Esmolol inhibits the stimulatory effects of norepinephrine and epinephrine. This leads to:
Common questions about Brevibloc
Esmolol is primarily used in hospital settings for the rapid control of heart rate and blood pressure. It is specifically indicated for supraventricular tachycardia (SVT), which is a condition involving a dangerously fast heart rhythm. It is also used during surgery to manage spikes in blood pressure or heart rate caused by anesthesia or the procedure itself. Because it works and wears off very quickly, it allows doctors to have precise control over a patient's cardiovascular status. It is not intended for long-term use at home.
The most common side effect of Esmolol is hypotension, or low blood pressure, which occurs in up to 50% of patients. Many patients also experience irritation or redness at the site where the IV is inserted. Some people may feel dizzy, sleepy, or nauseated during the infusion. Because the drug is processed so quickly, these side effects usually disappear within 10 to 30 minutes after the infusion is slowed or stopped. Medical staff monitor patients constantly to manage these effects as they happen.
No, you cannot drink alcohol while being treated with Esmolol. Esmolol is administered in a hospital environment for acute conditions where alcohol consumption is already prohibited. Alcohol can significantly increase the blood-pressure-lowering effects of Esmolol, which could lead to a dangerous drop in pressure or fainting. Furthermore, alcohol can interfere with the heart rhythms that Esmolol is trying to correct. Always wait until your doctor confirms the medication is out of your system before consuming alcohol.
Esmolol is considered a Category C medication, meaning its safety in pregnant women has not been fully established. It is generally only used during pregnancy if the mother's life is at risk due to a heart rhythm emergency. Potential risks include the baby having a slow heart rate or low blood sugar at birth. Doctors will carefully weigh the risks to the fetus against the necessity of the drug for the mother's health. If you are pregnant, ensure your medical team is aware before any procedures.
Esmolol works almost immediately when administered intravenously. Most patients will see a reduction in their heart rate or blood pressure within 2 to 5 minutes of starting the medication. This rapid onset is one of the main reasons it is used in emergency and surgical situations. Full steady-state effects are typically reached within 5 to 10 minutes if a loading dose is given. This allows for very quick adjustments to be made by the healthcare team.
Esmolol is meant to be stopped quickly, but this is always done under the supervision of a doctor. Because it has such a short half-life, the drug's effects disappear within 20 minutes of stopping the IV. However, if you are being treated for a fast heart rate, your doctor will usually start you on a longer-acting oral medication before stopping the Esmolol. This prevents the fast heart rate from returning (rebound tachycardia). Never attempt to interfere with your IV infusion pump.
In a clinical setting, Esmolol is given as a continuous infusion by medical professionals, so it is virtually impossible for a patient to 'miss a dose.' The infusion is controlled by an electronic pump that alerts staff if there is an interruption. If the infusion were to stop accidentally, the drug would leave your system within minutes. Your medical team would then restart the infusion and monitor you closely to regain control of your heart rate or blood pressure.
No, Esmolol does not cause weight gain. Weight gain is a side effect sometimes associated with long-term, oral beta-blocker therapy used for months or years. Esmolol is only used for short periods, typically less than 48 hours, in an intensive care or surgical setting. There is not enough time for the metabolic changes that lead to weight gain to occur. Any weight changes seen in the hospital are more likely due to IV fluids or other medical conditions.
Esmolol can interact with several other medications, particularly other heart drugs like Digoxin or calcium channel blockers (like Verapamil). These combinations can cause the heart rate to slow down too much. It can also interact with certain anesthetics used during surgery. Because it is given in a hospital, your doctors will check all your medications for potential interactions. It is vital to tell your medical team about every supplement and medication you were taking before admission.
Yes, Esmolol hydrochloride is available as a generic injection. The brand name version is known as Brevibloc. Both the brand and generic versions contain the same active ingredient and work in the exact same way. In most hospital settings, the generic version is used to manage costs while providing the same high level of care. Whether you receive the brand or generic, the monitoring and administration requirements remain the same.
Other drugs with the same active ingredient (Esmolol)
> Warning: Stop taking Esmolol and call your doctor immediately if you experience any of these.
Because Esmolol is only used for short-term, acute situations (usually less than 24-48 hours), there are no documented 'long-term' side effects like those seen with daily oral beta-blockers (e.g., weight gain, depression, or sexual dysfunction). The primary concern with prolonged infusion is the increased risk of vein irritation and potential accumulation of the acid metabolite in patients with kidney failure.
No FDA black box warnings for Esmolol. However, the FDA does emphasize 'Precautions' regarding its use in patients with certain pre-existing heart conditions and the absolute necessity of continuous blood pressure and ECG monitoring during administration.
Report any unusual symptoms to your healthcare provider immediately. Since you will be in a clinical setting, the nursing staff will be monitoring your vital signs constantly to detect these effects early.
Patients receiving Esmolol require the following clinical monitoring:
Since Esmolol is administered only in a hospital or surgical setting to patients who are acutely ill or undergoing procedures, patients will not be in a position to drive or operate machinery. After discharge, the effects of Esmolol will have worn off within an hour, but other medications (like anesthesia or oral heart meds) may still impair these activities.
Alcohol should not be consumed while Esmolol is being administered. Alcohol can enhance the blood-pressure-lowering effects of Esmolol, leading to a dangerous risk of fainting or cardiovascular collapse.
When stopping an Esmolol infusion, healthcare providers often 'taper' the dose while simultaneously starting an oral heart medication (like Metoprolol or Diltiazem). This ensures there is no 'gap' in heart rate control. Because of its 9-minute half-life, the drug is effectively gone from the body within 60 minutes of stopping the drip.
> Important: Discuss all your medical conditions with your healthcare provider before starting Esmolol. Ensure they are aware of any history of asthma or heart block.
Because Esmolol is only given intravenously, food interactions are not a primary concern. However, the overall nutritional status and hydration of the patient can affect how they respond to blood-pressure-lowering medications.
While patients are rarely taking supplements during an IV infusion of Esmolol, the following may have interacted if taken recently:
Esmolol is not known to significantly interfere with common laboratory tests (such as blood counts or liver panels). However, it may affect the results of a 'stress test' or any diagnostic test that relies on measuring the heart's maximum rate.
For each major interaction, the mechanism is usually pharmacodynamic (the drugs have similar or opposing effects on the body) rather than pharmacokinetic (how the body processes the drug), due to Esmolol's unique metabolism.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any heart or blood pressure medications you took at home before arriving at the hospital.
These conditions require a careful 'risk-benefit' analysis by the physician:
Patients who have had a severe allergic reaction to other beta-blockers (such as Metoprolol, Atenolol, or Labetalol) may have a cross-sensitivity to Esmolol. While the chemical structures differ slightly, the pharmacological class is the same, and caution is warranted.
> Important: Your healthcare provider will evaluate your complete medical history, including your current heart rhythm and lung function, before prescribing Esmolol.
Esmolol is not FDA-approved for use in children. The safety and effectiveness in the pediatric population have not been established. In rare cases where it is used off-label in a pediatric ICU, it requires extreme caution and weight-based dosing. Doctors monitor for effects on growth and development, although these are unlikely with short-term acute use.
Clinical studies of Esmolol did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. However, other clinical experience suggests that elderly patients are more prone to hypotension and bradycardia.
In patients with renal failure, the parent drug (Esmolol) is still cleared normally by the blood. However, the acid metabolite (ASL-8123) has a half-life that is increased tenfold in patients with end-stage renal disease (ESRD). While this metabolite is 1500 times less potent than Esmolol, its accumulation still warrants caution. It is not significantly removed by hemodialysis.
No special precautions are required for patients with liver disease. Because the metabolism occurs in the red blood cells, the liver's health does not dictate how fast the drug is cleared from the body. This makes Esmolol a preferred choice for heart rate control in patients with liver failure compared to other beta-blockers like Propranolol.
> Important: Special populations require individualized medical assessment. Always inform your medical team if you are pregnant, planning to become pregnant, or breastfeeding.
| Parameter | Value |
|---|---|
| Bioavailability | 100% (Intravenous) |
| Protein Binding | 55% |
| Half-life | 9 minutes |
| Tmax | Immediate (IV) |
| Metabolism | Red Blood Cell Esterases |
| Excretion | Renal (Metabolites) >70% |
Esmolol is classified as a Class II Antiarrhythmic and a Selective Beta-1 Blocker. It is grouped with other beta-blockers like Metoprolol and Atenolol, but it is unique due to its 'ultra-short-acting' status. In a hospital formulary, it is often categorized as an 'emergency cardiovascular agent.'